Search In this Thesis
   Search In this Thesis  
العنوان
Study of IL28B gene variation as a predictor of response to Directly Acting antiviral therapy in Hepatic transplantation Hepatitis C Egyptian Patients/
المؤلف
Ghait, Shady Samir Abdelhamid.
هيئة الاعداد
باحث / Shady Samir AbdelHamid Ghait
مشرف / Hanan Mahmoud Badawy
مشرف / Sherif Sadeq Taha
مشرف / Yaser Omar Abdelrahman
تاريخ النشر
2019.
عدد الصفحات
159 p. :
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
الطب الباطني
تاريخ الإجازة
1/1/2019
مكان الإجازة
جامعة عين شمس - كلية الطب - الباطنة العامة
الفهرس
Only 14 pages are availabe for public view

from 159

from 159

Abstract

This study was conducted on sixty (60) patients infected with HCV. Patient were recruited from outpatient clinics of Ain Shams university hospital, Ain Shams University specialized hospital and New Cairo hospital antiviral treating center between January 2016 and April 2018.
The selected patients were divided into 2 groups, each group will contain 30 patients as follows:
group 1: included 30 patients of recipients of liver transplantation and their graft donors (were treated for 24 weeks with sofosbuvir, ledipasvir and ribavirin regimen or sofosbuvir, daclatasvir and ribavirin regimen).
group 2: include 30 cirrhotic non-transplanted HCV patients (were treated for 24 weeks with sofosbuvir, ledipasvir and ribavirin regimen or sofosbuvir, daclatasvir and ribavirin regimen).
The aim of the work was to study IL28B gene polymorphism as a predictor of sustained virological response to different directly acting antiviral regimens in liver transplantation hepatitis C Egyptian patients versus the non transplanted cirrhotic patients.
The study details were discussed with the patient fulfilling the study criteria in order to obtain an informed concent.
All patients were subjected to:
1. Detailed history and clinical examination
2. Laboratory investigations:
 Complete blood picture (CBC)
 Liver biochemical profile: serum bilirubin (total and direct), serum creatinine, serum albumin, prothrombin time, transaminases (AST,ALT), and alkaline phosphatase and MELD score will be calculated.
3. Abdominal ultrasonography.
4. IL28B gene for both groups of patients before treatment. In the transplanted group it will be done for donors and recipients.
We have excluded patients with
1. Patients under 18 years.
2. Co-infection with HBV or HIV.
3. Patient with prior treatment of any antiviral treatment for HCV.
4. Female pregnant patients
5. Patients with renal impairment
6. Decompensated liver cirrhosis (child C).
The results of this study showed that:
Sustained virological response was found in 28 patients in group 1 (transplanted group) and 28 patients in group 2 (non-transplanted group) with no significant difference.
No significant difference also was found in both groups according to the type of regimen.
The result of HCV end treatment of recepients receiving sof-led (group A) vs recepients receiving sof-dacla (group B) in group 1 was the same with no statistical difference, both sub groups of patients showed 100% response and the SVR in both sub groups was the same with no statistical difference. Each subgroup had 1 relapser patient.
Also in this work the result of HCV end treatment of patients receiving sof-led (group A) vs patients receiving sof-dac (group B) in group 2 was the same with no statistical difference, both subgroups of patients showed 100% response and the SVR in both subgroups was the same with no statistical difference. Each subgroup had 1 relapser patient. The same as in subgroups of group 1.
The study showed also that the types of genotype CC, CT and TT of IL28B in donors and recipients were not significantly associated or affecting the results of SVR in group 1.
Interestingly, donor genotype seems not to influence the response pattern in recipients who have different IL28B genotype.
This means that there is no role of IL28B genotype in the response to directly acting antiviral drugs for hepatitis C recurrence in Egyptian patients.